Table 4 Comparison of clinicopathological characteristics between MUC5AC high-expression EPGA and MUC5AC low-expression EPGA.

From: Clinicopathological features and mucin expression of early papillary gastric adenocarcinoma

Characteristics

All (n = 116)

MUC5AC

P-value

High expression (n = 80)

Low expression (n = 36)

Age (years)

67 (59–71)

66.0 (58.3–71.0)

67.5 (61.5–72.0)

0.527

Sex

   

0.637

 Male

89

60 (75.0%)

29 (80.6%)

 

 Female

27

20 (25.0%)

7 (19.4%)

 

Location

   

0.167

 The cardia

20

13 (16.3%)

7 (19.4%)

 

 The fundus

4

4 (5.0%)

0 (0%)

 

 The corpus

24

20 (25.0%)

4 (11.1%)

 

 The pylorus

68

43 (53.8%)

25 (69.4%)

 

Gross appearance

   

0.029*

 Elevated

63

49 (61.3%)

14 (38.9%)

 

 Non-elevated

53

31 (38.8%)

22 (61.1%)

 

Ulcer formation

   

0.186

 Present

12

6 (7.5%)

6 (16.7%)

 

 Absent

104

74 (92.5%)

30 (83.3%)

 

Invasion depth

   

1.000

 Mucosa

94

65 (81.3%)

29 (80.6%)

 

 Submucosa

22

15 (18.8%)

7 (19.4%)

 

 Size (cm)

2.15 (1.60–3.18)

2.00 (1.53–3.08)

2.40 (1.63–3.45)

0.219

Differentiation

   

0.686

 Moderately

66

47 (59.7%)

19 (52.8%)

 

 Well

50

33 (41.3%)

17 (47.2%)

 

Infiltrative pattern

   

0.461

 INFa

96

68 (85.0%)

28 (77.8%)

 

 INFb

14

9 (11.3%)

5 (13.9%)

 

 INFc

6

3 (3.8%)

3 (8.3%)

 

LVI

   

0.034*

 Present

11

4 (5.0%)

7 (19.4%)

 

 Absent

105

76 (95.0%)

29 (80.6%)

 

LNM

   

0.094

 Present

2

0 (0%)

2 (5.6%)

 

 Absent

114

80 (100%)

34 (94.4%)

 

Histology

   

0.071

 High-grade

62

38 (47.5%)

24 (66.7%)

 

 Low-grade

54

42 (52.5%)

12 (33.3%)

 

MUC2

   

0.184

 High expression

20

11 (13.8%)

9 (25.0%)

 

 Low expression

96

69 (86.3%)

27 (75.0%)

 

MUC6

   

0.017*

 High expression

55

44 (55.0%)

11 (30.6%)

 

 Low expression

61

36 (45.0%)

25 (69.4%)

 

MSI status

   

0.088

 MSI-H

17

15 (18.8%)

2 (5.6%)

 

 MSI-L/MSS

99

65 (81.3%)

34 (94.4%)

 

 Ki-67

(positive index)

60% (50%~70%)

60% (50%~70%)

65% (50%~70%)

0.552

P53

   

0.414

 Wild type

69

50 (62.5%)

19 (52.8%)

 

 Mutation type

47

30 (37.5%)

17 (47.2%)

 
  1. *p < 0.05 with χ2 test or Fisher’s exact test (n < 5).
  2. Lymphovascular invasion, LVI; Lymph node metastasis, LNM; Microsatellite instability, MSI; Microsatellite instability-high/low, MSI-H/MSI-L; Microsatellite stable, MSS.